HK1081975A1 - Dimerized peptide - Google Patents
Dimerized peptideInfo
- Publication number
- HK1081975A1 HK1081975A1 HK06102442.4A HK06102442A HK1081975A1 HK 1081975 A1 HK1081975 A1 HK 1081975A1 HK 06102442 A HK06102442 A HK 06102442A HK 1081975 A1 HK1081975 A1 HK 1081975A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- peptide
- tumor antigen
- dimerized peptide
- antigen peptide
- dimerized
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003007122 | 2003-01-15 | ||
| PCT/JP2004/000254 WO2004063217A1 (ja) | 2003-01-15 | 2004-01-15 | 二量体化ペプチド |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1081975A1 true HK1081975A1 (en) | 2006-05-26 |
Family
ID=32709100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK06102442.4A HK1081975A1 (en) | 2003-01-15 | 2006-02-23 | Dimerized peptide |
| HK10107803.0A HK1141539A1 (en) | 2003-01-15 | 2010-08-16 | Dimerized peptide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10107803.0A HK1141539A1 (en) | 2003-01-15 | 2010-08-16 | Dimerized peptide |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060217297A1 (de) |
| EP (2) | EP2154145B1 (de) |
| JP (2) | JP4498274B2 (de) |
| KR (2) | KR20120054644A (de) |
| CN (2) | CN101851275A (de) |
| AT (1) | ATE444969T1 (de) |
| AU (1) | AU2004204031B2 (de) |
| BR (1) | BRPI0406800B8 (de) |
| CA (1) | CA2513701C (de) |
| DE (1) | DE602004023476D1 (de) |
| ES (1) | ES2332590T3 (de) |
| HK (2) | HK1081975A1 (de) |
| WO (1) | WO2004063217A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100767554B1 (ko) * | 1998-07-31 | 2007-10-17 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 억제 유전자 더블유티1의 생산물에 기초한 암항원 |
| EP1371664B1 (de) * | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti-modifiziertes peptid |
| EP1401472A4 (de) * | 2001-05-25 | 2005-04-06 | Univ Jefferson | Alternative splice-formen von proteinen als basis für multiple therapeutische modalitäten |
| WO2004024175A1 (ja) * | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| EP2186896B1 (de) * | 2004-03-31 | 2015-11-04 | International Institute of Cancer Immunology, Inc. | Von WT1 abgeleitete Krebs-Antigenpeptide |
| CN103169958A (zh) * | 2005-02-04 | 2013-06-26 | 萨瓦克公司 | 存活蛋白肽疫苗 |
| ES2352855T3 (es) * | 2005-11-30 | 2011-02-23 | International Institute Of Cancer Immunology, Inc. | Nuevos compuestos peptídicos del tumor de wilms. |
| DK2518149T3 (en) | 2006-02-22 | 2016-01-11 | Int Inst Cancer Immunology Inc | HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| PT1987063E (pt) * | 2006-02-23 | 2009-12-15 | Fibrex Medical Res & Dev Gmbh | Péptidos e derivados peptídicos, a produção destes bem como a sua utilização para a preparação de uma composição farmacêutica terapeuticamente e/ou preventivamente activa |
| CN102302788B (zh) | 2006-12-28 | 2016-06-15 | 株式会社癌免疫研究所 | Hla-a*1101限制的wt1肽及含有其的药物组合物 |
| RU2680539C2 (ru) | 2007-02-27 | 2019-02-22 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Способ активации хелперных т-клеток и композиция для применения в данном способе |
| ES2534434T3 (es) * | 2007-08-30 | 2015-04-22 | Curedm Group Holdings, Llc | Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos |
| US10654892B2 (en) | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| AU2011335551B2 (en) * | 2010-12-02 | 2016-10-06 | Bionor Immuno As | Peptide scaffold design |
| AU2011348396A1 (en) * | 2010-12-23 | 2013-07-04 | Valneva Austria Gmbh | OprF/I agents and their use in hospitalized and other patients |
| CA2821995C (en) * | 2011-01-06 | 2019-02-12 | Bionor Immuno As | Monomeric and multimeric peptides immunogenic against hiv |
| JP6082901B2 (ja) * | 2011-01-31 | 2017-02-22 | オリンパス株式会社 | ワクチン・アジュバント |
| ES2655031T3 (es) | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
| US9833493B2 (en) | 2012-12-17 | 2017-12-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| KR20150126042A (ko) | 2013-03-12 | 2015-11-10 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 액체 수성 조성물 |
| US10588952B2 (en) * | 2013-03-29 | 2020-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate vaccine using trimming function of ERAP1 |
| KR102121638B1 (ko) | 2013-03-29 | 2020-06-10 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Wt1 항원 펩티드 콘쥬게이트 백신 |
| US20160229894A1 (en) | 2013-10-17 | 2016-08-11 | Seoul National University R&Db Foundation | Alpha helix cell-penetrating peptide multimer, preparation method therefor and use therefor |
| EP3199175B1 (de) * | 2014-09-27 | 2022-03-23 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmazeutische zusammensetzung zur injektion |
| JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
| US20180140691A1 (en) * | 2015-05-20 | 2018-05-24 | Sumitomo Dainippon Pharma Co., Ltd. | Combination use of wt1 antigen peptide and immunomodulator |
| IL256880B2 (en) | 2015-07-14 | 2024-03-01 | Yeda Res & Dev | Combining proteins for the diagnosis of schizophrenia |
| WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
| US20240207426A1 (en) * | 2022-12-22 | 2024-06-27 | Defence Therapeutics Inc. | Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5779696A (en) * | 1995-06-01 | 1996-12-18 | Kishimoto, Tadamitsu | Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1) |
| JP3060287B2 (ja) | 1995-10-09 | 2000-07-10 | 参天製薬株式会社 | アパファントを主薬とする水性点眼剤 |
| KR100767554B1 (ko) * | 1998-07-31 | 2007-10-17 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 억제 유전자 더블유티1의 생산물에 기초한 암항원 |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| MY139226A (en) * | 1998-09-30 | 2009-08-28 | Corixa Corp | Compositions and methods for wt1 specific immunotherapy |
| GB9823897D0 (en) * | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| EP1371664B1 (de) * | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti-modifiziertes peptid |
| EP1447091A4 (de) * | 2001-09-28 | 2008-02-13 | Institute Of Can International | Neues verfahren zur induktion von antigen-spezifischen t-zellen |
| JPWO2003028758A1 (ja) * | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| ATE466084T1 (de) * | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
| CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| EP2186896B1 (de) | 2004-03-31 | 2015-11-04 | International Institute of Cancer Immunology, Inc. | Von WT1 abgeleitete Krebs-Antigenpeptide |
-
2004
- 2004-01-15 JP JP2005508011A patent/JP4498274B2/ja not_active Expired - Lifetime
- 2004-01-15 WO PCT/JP2004/000254 patent/WO2004063217A1/ja active Application Filing
- 2004-01-15 CN CN201010156098A patent/CN101851275A/zh active Pending
- 2004-01-15 EP EP09172205.8A patent/EP2154145B1/de not_active Expired - Lifetime
- 2004-01-15 KR KR1020127008760A patent/KR20120054644A/ko not_active Application Discontinuation
- 2004-01-15 ES ES04702444T patent/ES2332590T3/es not_active Expired - Lifetime
- 2004-01-15 EP EP04702444A patent/EP1584627B1/de not_active Expired - Lifetime
- 2004-01-15 CA CA2513701A patent/CA2513701C/en not_active Expired - Lifetime
- 2004-01-15 AT AT04702444T patent/ATE444969T1/de not_active IP Right Cessation
- 2004-01-15 BR BRPI0406800A patent/BRPI0406800B8/pt active IP Right Grant
- 2004-01-15 US US10/541,821 patent/US20060217297A1/en not_active Abandoned
- 2004-01-15 KR KR1020057012761A patent/KR101399678B1/ko active IP Right Grant
- 2004-01-15 AU AU2004204031A patent/AU2004204031B2/en not_active Expired
- 2004-01-15 DE DE602004023476T patent/DE602004023476D1/de not_active Expired - Lifetime
- 2004-01-15 CN CN2004800058473A patent/CN1756763B/zh not_active Expired - Lifetime
-
2006
- 2006-02-23 HK HK06102442.4A patent/HK1081975A1/xx not_active IP Right Cessation
-
2009
- 2009-11-16 JP JP2009260957A patent/JP4926231B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-07 US US12/795,187 patent/US8242084B2/en not_active Expired - Lifetime
- 2010-08-16 HK HK10107803.0A patent/HK1141539A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2004063217A1 (ja) | 2006-06-01 |
| KR101399678B1 (ko) | 2014-05-27 |
| CN1756763B (zh) | 2010-05-26 |
| EP1584627A4 (de) | 2006-03-15 |
| KR20050098863A (ko) | 2005-10-12 |
| US8242084B2 (en) | 2012-08-14 |
| JP4498274B2 (ja) | 2010-07-07 |
| CA2513701C (en) | 2013-06-18 |
| JP4926231B2 (ja) | 2012-05-09 |
| BRPI0406800A (pt) | 2006-01-17 |
| BRPI0406800B8 (pt) | 2021-05-25 |
| EP1584627A1 (de) | 2005-10-12 |
| EP2154145A2 (de) | 2010-02-17 |
| KR20120054644A (ko) | 2012-05-30 |
| EP2154145B1 (de) | 2013-04-24 |
| ES2332590T3 (es) | 2010-02-09 |
| AU2004204031A1 (en) | 2004-07-29 |
| CN1756763A (zh) | 2006-04-05 |
| AU2004204031B2 (en) | 2010-03-04 |
| HK1141539A1 (en) | 2010-11-12 |
| BRPI0406800B1 (pt) | 2020-08-11 |
| CA2513701A1 (en) | 2004-07-29 |
| CN101851275A (zh) | 2010-10-06 |
| US20060217297A1 (en) | 2006-09-28 |
| ATE444969T1 (de) | 2009-10-15 |
| US20100292164A1 (en) | 2010-11-18 |
| JP2010047603A (ja) | 2010-03-04 |
| EP2154145A3 (de) | 2010-05-19 |
| WO2004063217A1 (ja) | 2004-07-29 |
| DE602004023476D1 (de) | 2009-11-19 |
| BRPI0406800A8 (pt) | 2016-11-01 |
| EP1584627B1 (de) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1141539A1 (en) | Dimerized peptide | |
| WO2003102157A3 (en) | Synthetic antibody phage libraries | |
| WO2007064919A3 (en) | Binding polypeptides with restricted diversity sequences | |
| WO2005012531A3 (en) | Antibody cdr polypeptide sequences with restricted diversity | |
| HK1079979A1 (de) | ||
| WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
| HK1071898A1 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
| WO2005029076A3 (en) | Nanoparticle conjugates and method of production thereof | |
| RS51180B (sr) | Interleukin-10 antitela | |
| IL142025A0 (en) | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds | |
| CY1113850T1 (el) | Νεα παραγωγα ινσουλινης | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| GB0121591D0 (en) | Hybrid and tandem expression of neisserial proteins | |
| IL186265A0 (en) | Il-21 variants | |
| IL172729A0 (en) | Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins | |
| EP1983059A3 (de) | Reaktionsgemische zur Herstellung von Dipeptiden | |
| AU2003230603A1 (en) | Controlled modulation of amino acid side chain length of peptide antigens | |
| AU2002217010A1 (en) | Peptides, the production and use thereof for binding immunoglobulins | |
| BR0306715A (pt) | Métodos para diagnóstico e tratamento de tumores | |
| WO2003074546A3 (de) | Streptavidin-bindungspeptid | |
| WO2005037236A3 (en) | Novel heat shock protein 20-related polypeptides and uses therefor | |
| ATE467421T1 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
| GB0220805D0 (en) | Peptide monomers and protein structures | |
| DE60226277D1 (de) | Cytotoxisches protein und dessen verwendung | |
| WO2005078076A3 (en) | Tpl2 and its expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20240114 |